Study Says Meridia May Up Risk Of Heart Attack, Stroke

Law360, New York (September 2, 2010, 11:15 AM EDT) -- A study published Thursday in The New England Journal of Medicine warned that Abbott Laboratories’ weight-loss drug Meridia may increase the risk of nonfatal heart attack and stroke in some users, raising new concerns about the controversial pill just weeks before a U.S. advisory panel is set to consider its fate.

The Abbott-funded study found that Meridia — the brand name for sibutramine hydrochloride — could increase the chances of nonfatal heart attacks and strokes in obese users over the age of 55 years with preexisting...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.